Novartis stock holds steady after EAACI Rhapsido update. US trading stays in view.

By Christina Vaughn, Background & Management desk. Reviewed on June 30, 2026 at 2:37 p.m. ET.

Novartis AG (ISIN CH0012005267) is being watched after a Novartis press release via Via Ritzau said the company presented RemIND data at the EAACI Congress and described Rhapsido as the first targeted therapy to show efficacy across the three most common chronic inducible urticaria subtypes. The update gives the Swiss drugmaker a fresh clinical readout to frame alongside its U.S.-listed ADR, which keeps American investors in the story. For investors, the evidence now sits with the drug pipeline and the durability of the launch cadence.

Clinical readout

The release said the trial met its primary endpoints across the three subtypes, a point that matters because Novartis tied the message directly to Rhapsido's positioning in chronic inducible urticaria. The company also said the result came from a global Phase III study, which makes the data set more relevant than an early-stage signal.

Market context

Novartis shares in Switzerland last traded at CHF 126.20 on June 29, 2026, according to MarketScreener. The same feed showed a daily move of minus 0.06 percent and listed the stock's recent June 26 to June 29 price band, which leaves the chart constructive rather than stretched.

Pipeline and launch

Rhapsido is the product anchor here, and Novartis used the EAACI presentation to underline its clinical profile rather than its commercial scale. That matters because the market usually treats a clean Phase III message as a stronger support for revenue expectations than a preclinical update.

Swiss price check

As of June 29, 2026, Novartis traded at CHF 126.20 on the Swiss Exchange, based on the MarketScreener quote page. The move was small enough to keep attention on the data rather than on a dramatic price reaction.

This article was generated automatically and technically reviewed before publication. Market prices, analyst data and company information are provided without warranty and may change at short notice. This content is for informational purposes only and is not investment, financial, legal or tax advice. It is not a recommendation to buy or sell any security. Investing in securities involves risk, including the possible loss of principal.